Themis Chemicals Limited was incorporated in 1969 as a Limited Company
in the form of a Joint Venture between M/s Chemosyn Private Limited
and Medimpex Trading Company Ltd. (Medimpex). The joint venture had
technical and financial participation by Medimpex, a Hungarian
trading company for pharmaceuticals products.
Themis Chemicals Limited was incorporated with the aim of
manufacturing and marketing life saving drugs and their
In 1983-84, Mr Shantilal D. Patel and Mr. K.T. Lakdawala (one of the
promoters of Chemosyn Pvt. Ltd.), took over the management of the
Company by taking over the controlling share in the Company from
Chemosyn Private Ltd. The Company now operates as a joint venture
between Medimpex and the S.D. Pate Family. Since 1983-84 the Company
has been managed by Dr. Dinesh S. Patel, Mrs. Jayashree D.
Patel and other professionals under the guidance of Mr. S.D. Patel,
Mr.K.T.Lakdawala and other members of the Board.
In 1971, TCL started with the manufacture of Vitamin B12
(Cyanocobalamine) using anaerobic, non-sterile fermentation
technology. They were only the second Company in the world to
manufacture this product.
In the early 1970s the Company introduced formulations of the
anti-tuberculosis drug, Ethambutol Hydrochloride in the Indian
Market. Subsequently, the Company ventured into the manufacture of
formulations for various therapeutic groups.
The Company has also developed the technology for the production of
antibiotics such as Gentamycin, Rifampicin and Sisomicin using
in-house fermentation technology. TCL is engaged in the production
of high technology Synthetic Bulk Drugs like Ethambutol,
Pyrazinamide, Pyrithioxine and Phenylglycine derivatives.
At present the Company is engaged in manufacturing and selling of
synthetic bulk drugs and formulations. TCL operates in the
therapeutic segments of antituberculosis, cerebroactivators,
bronchodilators, antiasthmatic, anesthetic and other segments.
The antituberculosis bulk drugs and formulations constitute about 60%
of the turnover. TCL has a wide range of anti tuberculosis drugs.
The company ranks fourth in terms of turnover in this market (SOURCE
: ORG Retail Survey Audit (August 1994). The remaining turnover is
made of other bulk drugs, bulk drug intermediates and formulations in
anesthetic, appetite stimulant, bronohodilator, and other therapeutic
groups. The growth rates for the Company and the market for some of
the segments that it operates in are given below:
Market growth Brand growth Market
rate rate share
Ethambutol group 7.3% 28.7% 20.9%
group 10.6% 52.9% 6.7%
Terbutaline group 27.8% 65.6% 0.5%
SOURCE : ORG Retail Survey Audit (August 1994)
Some of the drugs introduced in the last year have been; Hemolok -
under license from Usolje Sibirsky Himpharmkombinat (A Russian
Institute). Centoblok - under license from Central Drug Research
The Company has also started exporting `Fumagillin', an antibacterial
product for veterinary use, for which it has a confirmed buy back
arrangement with Chinoin of Hungary.
The Company seeks to introduce new technology with the aim to produce
the latest drugs at competitive prices. For this purpose the Company
has a Research and Development Centre, which is approved by the
Department of Science and Technology, Government of India, so as to
keep pace with the newer developments in the field of biotechnology,
synthetic bulk drugs, natural products and formulations. The research
centre works in close co-operation with the various reputed Research
Laboratories of the country. The Company has not had any
strike/lockout in last 20 years in any of its plants.
The company has manufacturing facilities located at Vapi and
Hyderabad. The plant at Vapi manufactures intermediaries and bulk
drugs for the anti tuberculosis segment. Besides this, it
formulations in the tablet form, for anti tuberculosis and other
therapeutic segments. This plant also undertakes some contract
The facility at Hyderabad has been taken on a sublease arrangement
from an associate concern. This facility manufactures formulations
for various segments in the tablet, injectable and syrup forms.
MAIN OBJECTS OF THE COMPANY
The main objects of the Company as set out in the Memorandum &
Articles of Association and inter alia include;
1) To carry on business as manufacturers of all kinds of drugs,
pharmaceuticals, chemicals, fermentation products, natural products,
synthetic products, feed supplements, cosmetics, etc.
2) To develop and to acquire technical know how, receipts and
information to manufacture and right to process and manufacture
drugs, pharmaceuticals, and fine chemicals of all kinds, cosmetics,
natural and synthetic products, fermentation products, and feed
supplements of all kinds and of all forms, and to enter into
arrangements for use or
acquiring proprietary rights of trademarks, patents regarding above.
3) To carry on business as buyers, sellors, and dealers in all kinds
of medicines and medicinal preparations, drugs, chemicals, natural
and synthetic products, fermentation products, feed supplements and
cosmetics by wholesale and retail.
4) To acquire by purchase locally or by import or otherwise
manufacture for sale locally or by export or for consumption or use
by the company, or otherwise for trade in all goods and articles
usually used in the manufacture of drugs, pharmaceuticals, chemicals,
products, natural and synthetic products, feed supplements, extracts
5) To carry on the business of export and import of drugs, chemicals,
natural and synthetic products, feed supplements and cosmetics in all
kinds and all forms.
The Company does not have any subsidiaries.
-The Company proposes to change the name of the company from Themis
Chemicals Limited to Themis Medicare Limited.
-Mumbai-based Themis Medicare (TML) has completed the merger of
Artemis Biotech with itself
-Themis Medicare Ltd and Gedeon Richter Ltd (Budapest, Hungary) sign
an agreement on August 24, 2004 at Budapest to establish a Company for
manufacturing Active Pharmaceutical Ingredients (APIs) and
intermediates mainly for exports
-Themis Medicare Ltd has has signed an Agreement with M/s. Darou
Pakhsh Pharma Chem. (DPPC) of Iran
-Themis Medicare has commenced its formulation production at its new
manufacturing unit at Haridwar.
-Themis Medicare has developed a global first of its kind product -
-The Company had entered into an agreement with M/S Darou Pakhsh
Pharma Chem, (DPPC), Iran for erection and Technology supply in
connection with establishing a manufacturing facility for Statins in
-The company has designed E-mail ID for Investor Complaints as
-Themis Medicare has recommended dividend @ 25 %
- Themis Medicare Ltd has informed BSE that the Board of Directors of
the Company at its meeting held on January 30, 2009, inter alia, has
appointed Shri. Rajneesh Anand, as an Additional Director.
-Themis Medicare launched a combination of Lidocaine & Prilocaine in
'Spray' form under the brand name Lovelong
-Themis Medicare have introduced for the First Time in the Country a
'calcium' preparation with fruitygummies for paediatric use under the
brand name THEMIBEAR.
-The Company have introduced for the First Time in the country a
Multivitamin for Paediatric use under the brand name THEMIBEAR
-The Company have for the First Time entered into an altogether new
pharmaceutical marketing segment - COSMETO - DERMATOLOGY with the
launch of the brand LUMIXYL.
-License and Supply Agreement entered between Themis Medicare Limited
and Novartis India Limited on 26th March, 2013 whereby Themis has
agreed to supply Diclofenac topical gel formulated using a unique TPM
Transdermal Drug Delivery System.
-Supply & Distribution Agreement was entered between Themis Medicare
Ltd and Novartis India Ltd on 16th August, 2013 in terms of which
Novartis has agreed to purchase from Themis Diclofenac Sodium 75mg
per ml Injection in finished dosage pharmaceutical form
-Themis has invented Aquadol Spass 1ml Injection and has commenced
production, marketing & sales.